Sequential EGFR inhibition sensitizes glioblastoma to temozolomide.

Authors

Xiaozhou Yu, Runxin Wu, Shi-Yuan Cheng

Published in

Trends in pharmacological sciences. Aug 17, 2026. Epub Aug 17, 2026.

Abstract

Glioblastoma (GBM) remains a devastating disease for which standard temozolomide chemotherapy is limited by O⁶-methylguanine-DNA methyltransferase (MGMT)-mediated DNA damage repair. By targeting epidermal growth factor receptor (EGFR), a major oncogenic driver of GBM, Guo, Habib, and colleagues demonstrate that EGFR inhibition prior to temozolomide treatment induces an adaptive response that downregulates MGMT, enhancing therapeutic efficacy.

PMID:
42608284
Bibliographic data and abstract were imported from PubMed on 18 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.